Welcome to our dedicated page for Molecular Templates news (Ticker: MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.
Molecular Templates, Inc. (Nasdaq: MTEM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted therapeutics for oncology. The company leverages its innovative proprietary platform, engineered toxin bodies (ETBs), which are designed to selectively target and kill tumor cells, offering a novel approach to cancer treatment.
MTEM's leading immunotoxin, MT-3724, is in clinical development for non-Hodgkin's lymphoma. In addition to MT-3724, the company's robust pipeline includes MT-6402, targeting PD-L1, and MT-8421, targeting CTLA-4, both aimed at different forms of cancer. MT-0169, another advanced candidate, targets CD38 and is being developed for potential use in various oncology indications.
Recently, MTEM announced significant progress in its clinical trials. The first patient has been dosed in a Phase 1 clinical trial of MT-8421 for the treatment of advanced solid tumors. This study is a multi-center, open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-8421. The trial will enroll patients with tumors where CTLA-4 inhibitors have shown benefits, including melanoma, hepatocellular carcinoma, non-small cell lung cancer, and others.
MT-6402, another promising candidate, has shown encouraging results in Phase 1 studies, particularly in heavily pre-treated head and neck cancer patients. The drug demonstrated objective responses and evidence of tumor regression in patients who had progressed on multiple lines of treatment.
Financially, MTEM reported third-quarter 2023 revenues of $6.8 million, reflecting a notable increase from the previous year, driven primarily by collaborative research and development agreements. However, the company continues to operate at a net loss, with efforts focused on reducing operational costs and extending its cash runway into the second quarter of 2024.
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical firm, announced its participation in several upcoming September 2022 conferences focused on targeted biologic therapeutics. Key events include the Citi 17th Annual BioPharma Conference on September 7-8 in Boston, the H.C. Wainwright Global Investment Conference and Morgan Stanley Global Healthcare Conference on September 12-14 in New York, and the Cantor Oncology Conference on September 28 in New York. The company emphasizes its proprietary engineered toxin bodies (ETBs) as a novel therapeutic approach.
Molecular Templates, Inc. (MTEM) reported its Q2 2022 financial results, highlighting a net loss attributable to common shareholders of $24.4 million, up from $15.6 million in Q2 2021. Revenues decreased to $4.4 million from $15.1 million year-over-year, driven by collaborative agreements with Bristol Myers Squibb. R&D expenses remained stable at $21.4 million, while G&A expenses dropped to $6.6 million. As of June 30, 2022, MTEM had $104.4 million in cash, expected to fund operations until the end of 2023. The company continues developing its ETB pipeline with several upcoming milestones.
Molecular Templates presented findings on its Phase I programs for MT-6402 and MT-5111 at the 2022 ASCO meeting. The ongoing studies highlight the safety and unique biological effects of these engineered toxin bodies (ETBs) in treating advanced solid tumors. In MT-6402, 12 patients showed no dose-limiting toxicities, with promising pharmacodynamic effects observed. For MT-5111, 35 patients exhibited predictable dose-response relationships with no severe adverse events. These initial results indicate potential clinical benefits for both therapies.
Molecular Templates (Nasdaq: MTEM), a clinical-stage biopharmaceutical firm specializing in targeted biologic therapeutics, will attend two investor conferences. The first is the H.C. Wainwright Global Investment Conference, taking place virtually from May 23-26, 2022, with a presentation on May 24 at 7:00 AM ET. The second is the Jefferies Healthcare Conference in New York from June 8-10, 2022, featuring a fireside chat on June 9 at 2:00 PM ET. Webcast links for these events will be available on their corporate website.
Molecular Templates (MTEM) reported Q1 2022 results showing a net loss of $21.6 million, improving from $26.8 million in Q1 2021. Revenues increased to $8.5 million from $3.2 million, driven by collaborations with Takeda and Bristol Myers Squibb. Clinical advancements include dosing in Cohort 3 of the Phase 1 study of MT-6402, with further data expected later this year. The company has a cash reserve of $124.5 million, projected to sustain operations through the end of 2023.
Molecular Templates (Nasdaq: MTEM) presented multiple pipeline program highlights at the AACR Annual Meeting 2022. The focus was on engineered toxin bodies (ETBs), particularly MT-6402, which targets PD-L1 in patients with advanced solid tumors. The Phase I study showed promising pharmacodynamic effects, including T cell activation. Notable data included treatment of twelve patients, revealing dose-related effects and one dose-limiting toxicity. The company aims to expand ETB applications to other targets like CTLA-4 and TROP-2, leveraging unique immunological benefits to improve cancer therapies.
Molecular Templates, Inc. (MTEM), a clinical-stage biopharmaceutical company, will host a webinar on April 13, 2022, at 8:00 am ET. The event will feature Dr. David Spigel from the Sarah Cannon Research Institute discussing the company's innovative immuno-oncology approach targeting PD-L1 through its drug MT-6402, the first of its 3rd generation engineered toxin bodies (ETBs). This webinar also includes a company update and a Q&A session. MT-6402 aims to induce strong anti-tumor effects, potentially addressing limitations of existing checkpoint inhibitors.
Molecular Templates (MTEM) reported a net loss of $10.2 million ($0.18 per share) for Q4 2021, significantly improved from a $28.4 million loss in Q4 2020. Revenue surged to $18.0 million, up from $3.5 million, fueled by collaborations with Vertex and Bristol Myers Squibb. R&D expenses decreased to $19.3 million from $22.3 million year-over-year. Cash reserves stood at $152.0 million, sufficient to support operations through Q4 2023. The company continues to advance its ETB pipeline, with key data releases and IND filings anticipated throughout 2022.
Molecular Templates (Nasdaq: MTEM) announced the appointment of Gabriela Gruia, M.D. to its Board of Directors and the promotion of Megan Filoon to General Counsel. Dr. Gruia, an industry veteran with over 25 years in oncology drug development, enhances the board with her regulatory and clinical expertise. Previously, she held senior positions at Novartis and Ichnos Sciences. Filoon, who joined MTEM in 2018, has been instrumental in managing legal operations and will now lead the legal team as General Counsel. These changes are aimed at strengthening MTEM's leadership as it advances its engineered toxin body platform.
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company, will participate in several upcoming investor conferences. The key events include Cowen’s 42nd Annual Health Care Conference on March 8, 2022, Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022, and Barclays Global Healthcare Conference 2022 on March 15, 2022. Each conference will feature a corporate presentation, showcasing the company’s innovative engineered toxin bodies (ETBs) for cancer treatments. Webcast links will be available on their corporate website.
FAQ
What is the current stock price of Molecular Templates (MTEM)?
What is the market cap of Molecular Templates (MTEM)?
What does Molecular Templates, Inc. specialize in?
What is MT-3724?
What recent achievements has MTEM announced?
What is the status of MT-6402?
How is MTEM performing financially?
What is the ETB platform?
What types of cancer is MTEM targeting with its therapies?
Who are some of MTEM's key executives?
What collaborations does MTEM have?
Where can I find more information about MTEM?
